Related Experiment Video

Updated: Apr 29, 2026

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
07:44

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

1.1K

Management of central nervous system tumours in children

N J Thorp1, R E Taylor2

  • 1Clatterbridge Cancer Centre, Bebington, Wirral CH63 4JY, UK.

Clinical Oncology (Royal College of Radiologists (Great Britain))
|May 27, 2014
PubMed

Insights

This review covers current central nervous system (CNS) tumor management strategies for pediatric patients. It focuses on key considerations unique to childhood brain and spinal cord tumors.

Area of Science:

  • Pediatric Oncology
  • Neuro-oncology
  • Childhood Cancer Research

Background:

  • Central nervous system (CNS) tumors are the most common solid tumors in children.
  • Management requires a multidisciplinary approach tailored to pediatric neuro-oncology.
  • Significant advancements have been made, necessitating updated reviews.

Purpose of the Study:

  • To review current management strategies for pediatric CNS tumors.
  • To highlight aspects specific to the pediatric population.
  • To provide an overview for clinicians and researchers in pediatric neuro-oncology.

Main Methods:

  • Literature review of recent studies and clinical guidelines.
  • Synthesis of information on diagnosis, treatment, and supportive care.
  • Focus on age-specific challenges and outcomes.

Main Results:

  • Current management involves a combination of surgery, radiation, and chemotherapy.
  • Treatment protocols are increasingly specialized based on tumor type and molecular characteristics.
  • Long-term neurodevelopmental and quality-of-life outcomes are critical considerations.

Conclusions:

  • Effective management of pediatric CNS tumors requires tailored, multidisciplinary care.
  • Ongoing research is crucial for improving survival rates and reducing treatment toxicity.
  • Personalized medicine approaches are transforming the landscape of pediatric neuro-oncology.

Keywords:
Brainpaediatricradiotherapytumours

More Related Videos

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

7.1K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.6K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
552
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
409